Early Warning System for Bloodstream Infections in Children with Leukemia Shows Promise
A new test utilizing microbial cell-free DNA sequencing (mcfDNA-Seq) offers the potential to predict bloodstream infections in children undergoing treatment for high-risk leukemia days before symptoms appear, according to research published in The Lancet Microbe. This breakthrough could allow for earlier intervention and improved outcomes for vulnerable patients.
The Threat of Bloodstream Infections in Leukemia Patients
Bloodstream infections pose a significant threat to children with leukemia. Chemotherapy weakens the immune system, making patients susceptible to even common bacteria and fungi. These infections can rapidly escalate to sepsis, leading to prolonged hospital stays, delays in chemotherapy, and, in severe cases, mortality. Currently, clinicians lack a reliable method to identify these infections before symptoms manifest.
How mcfDNA-Seq Works
Researchers at St. Jude Children’s Research Hospital developed mcfDNA-Seq, a technology that detects fragments of microbial DNA circulating in the blood. In a prospective study, they analyzed daily plasma samples from 158 pediatric patients with high-risk leukemia, examining samples up to seven days before and at the time of a bloodstream infection diagnosis.
Study Findings
The study revealed that mcfDNA-Seq successfully predicted bloodstream infections in just over half of cases up to three days before symptoms emerged. The test accurately identified common infection-causing bacteria and fungi and demonstrated a high degree of accuracy in ruling out infection in healthy or uninfected patients (93.8%).
Potential Impact and Future Directions
“We’re not good at predicting or preventing infections in children with cancer, and the consequences can be deadly, causing lasting damage or delaying chemotherapy, which reduces the chances of successful treatment,” said Joshua Wolf, PhD, MBBS, of St. Jude Department of Infectious Diseases.
The findings suggest that mcfDNA-Seq could become a proactive tool for infection management in children receiving intensive cancer therapy. Early detection could enable clinicians to initiate treatment sooner, potentially preventing serious complications, reducing hospitalizations, and improving survival rates.
“The infections we detect are the same ones that can cause sepsis and death,” Wolf stated. “These findings provide a potential way to improve survival and outcomes for children with cancer or undergoing bone marrow transplantation.”
Further clinical trials are necessary to determine the best way to integrate this approach into treatment decisions. Researchers are now focused on developing strategies to effectively utilize the information provided by mcfDNA-Seq to guide preemptive treatment.
About St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is dedicated to advancing cures and prevention for childhood catastrophic diseases, including cancer, blood disorders, and infectious diseases. Through research and compassionate care, St. Jude aims to improve the lives of children worldwide.
Source: prnewswire.com